osimertinib,tepotinib
astrazeneca,merck
['osimertinib', 'vance,(-advance),(-observance)', 'insight 2', 'confirm,(-confirma),(-confirme),(-confirmi)']
insight 2 trial presented by at confirms relevance of metamp in osimertinib resistant egfrmut+ and suggests that continued blocking of egfr is needed 
Born in Majorca. Medical oncologist. Clinical researcher. Focused in lung cancer. World citizen. Major concerns: human inequality and blue planet environment